Literature DB >> 24190690

Genetic basis of MPN: Beyond JAK2-V617F.

Nicole C C Them1, Robert Kralovics.   

Abstract

The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by genetic alterations, often affecting cytokine signaling and gene expression. This review outlines somatic changes discovered in myeloproliferative neoplasms and how these genetic aberrations influence the pathogenesis of myeloproliferative neoplasms. Furthermore, genetic responses to drug treatments in myeloproliferative neoplasms are discussed.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24190690     DOI： 10.1007/s11899-013-0184-z

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  99 in total

1.  Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.

Authors:  Joannah Score; Claire Hidalgo-Curtis; Amy V Jones; Nils Winkelmann; Alison Skinner; Daniel Ward; Katerina Zoi; Thomas Ernst; Frank Stegelmann; Konstanze Döhner; Andrew Chase; Nicholas C P Cross
Journal:  Blood       Date:  2011-11-03       Impact factor: 22.113

2.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

3.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

4.  Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression.

Authors:  Thorsten Klampfl; Ashot Harutyunyan; Tiina Berg; Bettina Gisslinger; Martin Schalling; Klaudia Bagienski; Damla Olcaydu; Francesco Passamonti; Elisa Rumi; Daniela Pietra; Roland Jäger; Lisa Pieri; Paola Guglielmelli; Ilaria Iacobucci; Giovanni Martinelli; Mario Cazzola; Alessandro M Vannucchi; Heinz Gisslinger; Robert Kralovics
Journal:  Blood       Date:  2011-04-29       Impact factor: 22.113

5.  High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations.

Authors:  Frank Stegelmann; Lars Bullinger; Martin Griesshammer; Karlheinz Holzmann; Marianne Habdank; Susanne Kuhn; Carmen Maile; Stefanie Schauer; Hartmut Döhner; Konstanze Döhner
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

6.  Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

Authors:  Francis H Grand; Claire E Hidalgo-Curtis; Thomas Ernst; Katerina Zoi; Christine Zoi; Carolann McGuire; Sebastian Kreil; Amy Jones; Joannah Score; Georgia Metzgeroth; David Oscier; Andrew Hall; Christian Brandts; Hubert Serve; Andreas Reiter; Andrew J Chase; Nicholas C P Cross
Journal:  Blood       Date:  2009-04-22       Impact factor: 22.113

7.  Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.

Authors:  Franca Radaelli; Francesco Onida; Francesca G Rossi; Vittorio R Zilioli; Mariangela Colombi; Patrizia Usardi; Rossella Calori; Alberto Zanella
Journal:  Hematology       Date:  2008-08       Impact factor: 2.269

8.  Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1.

Authors:  Mamta Tahiliani; Kian Peng Koh; Yinghua Shen; William A Pastor; Hozefa Bandukwala; Yevgeny Brudno; Suneet Agarwal; Lakshminarayan M Iyer; David R Liu; L Aravind; Anjana Rao
Journal:  Science       Date:  2009-04-16       Impact factor: 47.728

9.  Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor.

Authors:  N A Nicola; D Metcalf; M Matsumoto; G R Johnson
Journal:  J Biol Chem       Date:  1983-07-25       Impact factor: 5.157

10.  Detectable clonal mosaicism from birth to old age and its relationship to cancer.

Authors:  Cathy C Laurie; Cecelia A Laurie; Kenneth Rice; Kimberly F Doheny; Leila R Zelnick; Caitlin P McHugh; Hua Ling; Kurt N Hetrick; Elizabeth W Pugh; Chris Amos; Qingyi Wei; Li-e Wang; Jeffrey E Lee; Kathleen C Barnes; Nadia N Hansel; Rasika Mathias; Denise Daley; Terri H Beaty; Alan F Scott; Ingo Ruczinski; Rob B Scharpf; Laura J Bierut; Sarah M Hartz; Maria Teresa Landi; Neal D Freedman; Lynn R Goldin; David Ginsburg; Jun Li; Karl C Desch; Sara S Strom; William J Blot; Lisa B Signorello; Sue A Ingles; Stephen J Chanock; Sonja I Berndt; Loic Le Marchand; Brian E Henderson; Kristine R Monroe; John A Heit; Mariza de Andrade; Sebastian M Armasu; Cynthia Regnier; William L Lowe; M Geoffrey Hayes; Mary L Marazita; Eleanor Feingold; Jeffrey C Murray; Mads Melbye; Bjarke Feenstra; Jae H Kang; Janey L Wiggs; Gail P Jarvik; Andrew N McDavid; Venkatraman E Seshan; Daniel B Mirel; Andrew Crenshaw; Nataliya Sharopova; Anastasia Wise; Jess Shen; David R Crosslin; David M Levine; Xiuwen Zheng; Jenna I Udren; Siiri Bennett; Sarah C Nelson; Stephanie M Gogarten; Matthew P Conomos; Patrick Heagerty; Teri Manolio; Louis R Pasquale; Christopher A Haiman; Neil Caporaso; Bruce S Weir
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330
View more
  5 in total

Review 1.  Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.

Authors:  Archana Agarwal; Kerry Morrone; Matthias Bartenstein; Zhizhuang Joe Zhao; Amit Verma; Swati Goel
Journal:  Stem Cell Investig       Date:  2016-02-26

Review 2.  Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.

Authors:  Anna Orlova; Bettina Wingelhofer; Heidi A Neubauer; Barbara Maurer; Angelika Berger-Becvar; György Miklós Keserű; Patrick T Gunning; Peter Valent; Richard Moriggl
Journal:  Expert Opin Ther Targets       Date:  2017-11-24       Impact factor: 6.902

Review 3.  Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.

Authors:  S Cerquozzi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-11-13       Impact factor: 11.037

Review 4.  Epigenetics in Myeloproliferative Neoplasms.

Authors:  Suzanne McPherson; Mary Frances McMullin; Ken Mills
Journal:  J Cell Mol Med       Date:  2017-07-04       Impact factor: 5.310

5.  Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation.

Authors:  Maira da Costa Cacemiro; Juçara Gastaldi Cominal; Raquel Tognon; Natalia de Souza Nunes; Belinda Pinto Simões; Lorena Lôbo de Figueiredo-Pontes; Luiz Fernando Bazzo Catto; Fabíola Traina; Elizabeth Xisto Souto; Fabiana Albani Zambuzi; Fabiani Gai Frantz; Fabíola Attié de Castro
Journal:  Hematol Transfus Cell Ther       Date:  2018-02-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.